Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 20/20 | 0.73 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.69 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.69 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.69 |
| ▸ | F10 | P00742 | 1/20 | 0.55 |
| ▸ | PLAT | P00750 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7643080 | 0.95 | F2 (0.75) | F2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL7401128 | 0.92 | F2 (0.71) | F2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL7643508 | 0.88 | F2 (0.84) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL7639399 | 0.88 | F2 (0.75) | F2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL7404951 | 0.88 | F2 (0.70) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL7447701 | 0.88 | F2 (0.75) | F2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL6957150 | 0.83 | F2 (0.75) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL7159400 | 0.80 | F2 (0.73) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL6957416 | 0.79 | F2 (0.70) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL7155849 | 0.79 | F2 (0.75) | F2PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6462050-B1 | FOR TREATING OR PREVENTING VENOUS, CARDIOGENIC, AND ARTERIAL THROMBOSIS/EMBOLISM, ATHERSCLEROSIS, AND FOR LOWERING PROPENSITY OF DEVICES THAT COME INTO CONTACT WITH BLOOD TO CLOT BLOOD | MERCK & CO., INC. | 2002-10-08 | — | — | US | disclosed |
| US-20020035115-A1 | Thrombin inhibitors | MERCK SHARP & DOHME CORP. | 2002-03-21 | — | — | US | disclosed |
| WO-2002009711-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035115-A1 | Thrombin inhibitors | TFPI, PLAT, F2 | F2 3/4885PRSS1 55/4885PRSS2 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.